Table 3 The methylation of the gene promoters in glioma patients and their clinical characteristics
From: MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma
Variable | Methylation n (%) | Â | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | ANKDD1A | GAD1 | HIST1H3E | PCDHA8 | PCDHA13 | PHOX2B | SIX3 | SST |
Sex | Â | Â | Â | Â | Â | Â | Â | Â |
   Male | 18 (64.3) | 15 (53.6) | 25 (89.3) | 13 (65.0) | 20 (76.9) | 19 (67.9) | 19 (67.9) | 27 (96.4) |
   Female | 11 (91.7) | 9 (75.0) | 9 (75.0) | 7 (70.0) | 9 (75.0) | 10 (83.3) | 10 (83.3) | 11 (91.7) |
p- vablue | 0.076 | 0.205 | 0.246 | 0.784 | 0.897 | 0.315 | 0.315 | 0.527 |
Age | Â | Â | Â | Â | Â | Â | Â | Â |
   < 45 y | 18 (90.0) | 13 (65.0) | 17 (85.0) | 12 (60.0) | 17 (85.0) | 18 (90.0) | 14 (70.0) | 19 (95.00 |
   ≥45 y | 11 (55.0) | 11 (55.0) | 17 (85.0) | 8 (40.0) | 12 (60.0) | 11(55.0) | 15 (75.0) | 19 (95.0) |
p- vablue | 0.013 * | 0.519 | 1.000 | 0.121 | 0.077 | 0.013 * | 0.723 | 1.000 |
Differentiation | Â | Â | Â | Â | Â | Â | Â | Â |
   Grade I-II | 20 (90.9) | 16 (72.7) | 19 (86.4) | 14 (63.6) | 18 (81.8) | 19 (86.4) | 18 (81.8) | 22 (100.0) |
   Grade III-IV | 9 (50.0) | 8 (44.4) | 15 (83.3) | 6 (54.5) | 11 (68.8) | 10 (55.6) | 11 (68.8) | 16 (88.9) |
p- vablue | 0.004 ** | 0.069 | 0.789 | 0.425 | 0.350 | 0.030 * | 0.145 | 0.109 |
Tumor type | Â | Â | Â | Â | Â | Â | Â | Â |
   A | 22 (73.3) | 18 (60.0) | 27 (90.0) | 15 (68.2) | 22 (73.3) | 23 (76.7) | 20 (66.7) | 29 (96.7) |
   GBM | 3 (50.0) | 3 (50.0) | 4 (66.7) | 2 (50.0) | 4 (100.0) | 3 (50.0) | 5 (83.3) | 5 (83.3) |
   OA | 4 (100.0) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 4 (100.0) | 4 (100.0) |
p- vablue | 0.217 | 0.732 | 0.289 | 0.723 | 0.498 | 0.407 | 0.304 | 0.349 |